D. Medical Industries Ltd., an Israeli medical device company engaged through its subsidiaries in the research, development, manufacture and sale of innovative products for diabetes treatment and drug delivery, announced today that it has worked out a deal to distribute its Spring(TM) Universal Infusion Sets in the United States. D. Medical’s subsidiary, Spring Health Solutions Inc., has agreed to give RGH Enterprises, Inc., the parent company of Edgepark Medical Supplies and Independence Medical, a non-exclusive distribution deal for the Infusion Sets to facilitate the product’s immediate commercial rollout in the world’s single largest insulin pump and disposables market.
The Spring Universal Infusion Set features a hidden, auto-retractable needle, 360 connector and the smallest, one-click, all-in-one inserter. The core of the Spring Universal Infusion Set is the proprietary
Detach-Detect mechanism. In the case the base of the infusion set detaches from the user’s body, a blocking mechanism is triggered which creates an occlusion and sets off an alarm in an insulin pump. This unique feature enables exceptional reliability for continuously controlled and monitored insulin delivery, providing additional safety and peace of mind – especially for athletes and the parents of pediatric patients. The Spring Universal Infusion Set works with most insulin pumps on the market today.
“The annual market for infusion sets is estimated to total $730 million in the U.S. alone – yet there has been little or no design innovation in this category in recent past. We believe that the clear advantages of our Spring Universal Infusion sets, combined with the fact that they will be available through a market leaders like Edgepark Medical Supplies and Independence Medical, will lead to maximized penetration into what was, heretofore a largely commoditized product market,” said Efri Argaman, D. Medical’s Chief Executive Officer, in a press release today.
The United States has approximately 26 million diabetes patients with 1.4 million suffering from Type 1 diabetes and about 350,000 currently rely on insulin pump therapy for treatment. A recent U.S. Centers for Disease Control and Prevention report estimated that 1 in 3 Americans will have diabetes by 2050 if current trends continue.
D. Medical is focused on research and development that will lead to the next generation of insulin pumps. To learn more about D. Medical’s research, please visit www.dmedicalindustries.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
